Lower baseline soluble PD-L1 levels correlate with improved progression-free and overall survival in NSCLC
Blood Marker May Predict Lung Cancer Outcomes
This meta-analysis of 1967 patients with non-small cell lung cancer (NSCLC) found that lower baseline sPD-L1 levels are associated with sign…
A protein in the blood called sPD-L1 may help predict how well lung cancer patients respond to treatment.
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
New Guidelines Redefine Surgery Options for Lung Cancer Patients
This clinical guideline addresses the management of stage III non-small cell lung cancer (NSCLC). It advocates for a multidisciplinary appro…
New guidelines suggest that surgery for certain lung cancers should be based on tumor biology and treatment response rather than just anatom…
Ensartinib improves 24-month disease-free survival to 86.4% in resected ALK-positive NSCLC
New drug shows promise for specific type of lung cancer
This Phase 3 randomized trial of 274 patients with resected, ALK-positive stage IB to IIIB NSCLC found that ensartinib (225 mg once daily) s…
A new medication called ensartinib significantly improved the time patients lived without their lung cancer returning after surgery.
PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
Adding PD-1 inhibitors to chemotherapy improves lung cancer survival
This network meta-analysis of 20 randomized controlled trials evaluated treatments for driver gene-negative non-small cell lung cancer with …
Combining a specific immunotherapy drug with chemotherapy may help patients with certain types of lung cancer and liver spread live longer.
TROP2-targeting ADCs achieve 50.6% ORR in EGFR-mutant NSCLC following tyrosine kinase inhibitor failure
Antibody-drug conjugates show promise for lung cancer after TKI failure
This systematic review and meta-analysis of 1092 patients found that antibody-drug conjugates (ADCs) provide significant clinical benefits f…
New research highlights how specific antibody-drug conjugates may offer better outcomes for patients with certain types of lung cancer.
Primary and acquired resistance to immune checkpoint inhibitors in NSCLC involves antigen presentation and TME remodeling
Understanding why some lung cancer treatments do not work for every patient
This systematic review synthesizes mechanisms of primary and acquired resistance to PD-1/PD-L1 inhibitors in patients with non-small cell lu…
Doctors are studying why certain immune-boosting drugs fail to stop lung cancer growth. New insights help find better ways to treat patients…
Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Analysis shows PD-1 inhibitors may outperform PD-L1 for lung cancer
A meta-analysis suggests that PD-1 inhibitors combined with chemotherapy offer superior survival outcomes compared to PD-L1 inhibitors plus …
A large analysis of over 14,000 patients suggests that certain types of immunotherapy combined with chemotherapy may offer better survival r…
Single-cell and spatial omics provide detailed mapping of tumor-immune ecosystems in non-small cell lung cancer
New Mapping Tools May Improve Lung Cancer Treatment Planning
This mini review explores how single-cell RNA sequencing, chromatin profiling, and spatial transcriptomics offer superior resolution for ana…
Advanced mapping techniques are helping researchers identify how lung cancer cells adapt and hide from current treatments to help plan bette…
Nivolumab plus chemotherapy improves pathological complete response in resectable NSCLC with PD-L1 < 1%
Nivolumab plus chemotherapy improves pathological response in certain lung cancers
This network meta-analysis of 1012 patients with resectable non-small cell lung cancer (NSCLC) and PD-L1 expression < 1% found that nivoluma…
A new analysis shows that adding nivolumab to chemotherapy can improve specific cancer responses for patients with low PD-L1 levels.
Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Combination therapy extends progression free survival in lung cancer
Phase 3 trial results show aumolertinib plus chemotherapy significantly extends progression-free survival compared to monotherapy for advanc…
A new trial shows that combining a specific drug with chemotherapy helps patients with advanced lung cancer live longer without their diseas…
Osimertinib treatment for EGFR-mutated NSCLC results in hypertension as the most common CVAE
Osimertinib treatment for lung cancer shows specific heart risks
This meta-analysis of 10,316 patients with EGFR-mutated non-small cell lung cancer evaluated cardiovascular adverse events (CVAEs) associate…
New data identifies hypertension as the most common heart-related side effect for patients taking osimertinib for certain types of lung canc…
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients
Combined Treatments May Help Manage Brain Metastases in Lung Cancer
This case report and literature review describes a patient with EGFR-mutant NSCLC and brain/leptomeningeal metastases. The authors suggest t…
A new treatment approach combining surgery, local chemotherapy, and targeted drugs may help manage brain cancer spread for some patients.
Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer
Immunotherapy Combined With Chemoradiotherapy Shows Promise for Lung Cancer
This meta-analysis of randomized controlled trials evaluated the impact of chemoradiotherapy (CCRT) plus immunotherapy on 1,853 patients wit…
Adding immunotherapy to standard chemoradiotherapy shows a favorable trend in survival for patients with limited-stage small-cell lung cance…
Sotorasib resistance linked to transformation to pulmonary giant cell carcinoma in KRAS G12C lung adenocarcinoma
Lung cancer can change form after targeted drug treatment
A case report with literature review describes a 71-year-old man with KRAS G12C-mutant lung adenocarcinoma whose tumor transformed to pulmon…
A man's lung cancer transformed into a more aggressive type after taking the targeted drug sotorasib, highlighting the need for re-biopsy wh…
CT-based deep learning models show high accuracy predicting EGFR mutation status in lung adenocarcinoma
Machine learning models help predict lung cancer mutations from scans
This meta-analysis of 6,628 Chinese patients with lung adenocarcinoma found that machine learning-based radiomics models provide a noninvasi…
New analysis shows that deep learning models can accurately identify specific lung cancer mutations using standard CT scans.
Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer
Nab-paclitaxel shows similar results to paclitaxel for lung cancer
This meta-analysis examined paclitaxel monotherapy in relapsed small cell lung cancer. The 3-month progression-free survival rate was modest…
New data compares two types of paclitaxel treatments for relapsed small cell lung cancer, showing similar safety and effectiveness.
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
High ADAM9 levels linked to worse lung cancer survival in new data
This research article is an observational study with in vitro experiments analyzing TCGA-LUAD datasets from 517 tumor and 59 normal tissues.…
High ADAM9 expression linked to immunosuppression and poorer survival in lung adenocarcinoma patients based on tissue data and lab experimen…
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Questions about Non-Small Cell Lung Cancer
Can morning timing of immune checkpoint infusions improve survival outcomes in metastatic non-small cell lung cancer patients?
Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear benefits.
Full answer →Does a phase III trial show sublobar resection is better than lobectomy for small peripheral non–small cell lung cancer?
Yes, a phase III trial (CALGB 140503) found sublobar resection noninferior to lobectomy for disease-free survival in small peripheral NSCLC ≤2 cm.
Full answer →How do bispecific antibodies and CAR T-cell therapy work for advanced non–small cell lung cancer?
Bispecific antibodies and CAR T-cell therapy are two immunotherapies being tested for advanced NSCLC; bispecific antibodies show more clinical progress, while CAR T faces challenges like toxicity and tumor trafficking.
Full answer →What does the research say about using chemotherapy versus immunotherapy for advanced Non-Small Cell Lung Cancer?
For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.
Full answer →How does high PD-L1 expression affect treatment choices for advanced Non-Small Cell Lung Cancer?
High PD-L1 expression (≥50%) often makes immunotherapy, such as pembrolizumab, a first-line option for advanced NSCLC, but other factors like mutations also guide treatment.
Full answer →Can you explain the global disparities in access to new therapies for advanced Non-Small Cell Lung Cancer?
Global disparities in access to new NSCLC therapies stem from differences in drug approval, cost, testing infrastructure, and healthcare system resources.
Full answer →Is camrelizumab associated with a higher risk of disease progression compared to pembrolizumab?
In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one real-world study.
Full answer →Does real-world data support using pembrolizumab for my advanced Non-Small Cell Lung Cancer?
Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of 21 months and 29% survival at 5 years.
Full answer →All Non-Small Cell Lung Cancer Articles
- Lower baseline soluble PD-L1 levels correlate with improved progression-free and overall survival in NSCLC
- Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
- Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
- Ensartinib improves 24-month disease-free survival to 86.4% in resected ALK-positive NSCLC
- PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
- TROP2-targeting ADCs achieve 50.6% ORR in EGFR-mutant NSCLC following tyrosine kinase inhibitor failure
- Primary and acquired resistance to immune checkpoint inhibitors in NSCLC involves antigen presentation and TME remodeling
- Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
- Single-cell and spatial omics provide detailed mapping of tumor-immune ecosystems in non-small cell lung cancer
- Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
- Nivolumab plus chemotherapy improves pathological complete response in resectable NSCLC with PD-L1 < 1%
- Sublobar resection associated with improved overall survival compared to SBRT in early-stage non-small cell lung cancer
- Osimertinib treatment for EGFR-mutated NSCLC results in hypertension as the most common CVAE
- Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
- ALK tyrosine kinase inhibitors achieve 58.5% objective response rate in ALK-positive non-small cell lung cancer
- Intrathecal chemotherapy provides objective response rates of 34.5% to 86.4% in non-small-cell lung cancer leptomeningeal metastasis
- Sacituzumab Tirumotecan Combined With Pembrolizumab Improves Outcomes in PD-L1 Positive NSCLC
- High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
- CRT plus EGFR-TKI improves overall survival while EGFR-TKI plus RT ranks first for progression-free survival
- Statin use and EGFR-TKI efficacy in EGFR-mutant non-small cell lung cancer remains to be evaluated
- Fissios App plus physiotherapy aims to cut postoperative complications in NSCLC surgery
- Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
- OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
- Meta-analysis shows sublobar resection linked to worse survival outcomes compared with lobectomy for early-stage non-small cell lung cancer patients
- Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
- Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
- Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
- Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
- Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
- Perspective review on radiation therapy and cardiac toxicity in lung cancer
- Review of Non-small cell lung cancer without reported intervention or outcomes
- Systematic review and meta-analysis on neoadjuvant chemoimmunotherapy for resectable NSCLC
- Meta-analysis links emotional distress to worse outcomes in advanced lung cancer
- Systematic review and meta-analysis links higher prognostic nutritional index to better survival in non-small cell lung cancer
- Systematic review of intrathecal therapy for leptomeningeal metastasis in non-small cell lung cancer
- Morning immune checkpoint inhibitor infusions associated with improved survival in metastatic non-small-cell lung cancer
- Meta-analysis of PET/CT metabolic parameters for predicting NSCLC response after neoadjuvant therapy
- FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
- Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1
- Meta-analysis shows dual ICI therapy improves survival in advanced metastatic non-small cell lung cancer
- Post hoc reanalysis suggests stereotactic radiotherapy may improve local control in medically inoperable Stage I non-small cell lung cancer
- Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
- Narrative review explores Vaccinia virus therapy for non-small cell lung cancer with noted delivery challenges
- FDA Approves Lazcluze (lazertinib) with Amivantamab for EGFR-Mutant NSCLC
- Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
- Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
- Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
- RNK08954 shows unconfirmed responses in KRASG12D-mutant NSCLC and PDAC in Phase Ia trial
- Subcutaneous tislelizumab shows comparable trough concentrations to intravenous dosing in treatment-naive advanced non-small cell lung cancer patients
- Combination therapy shows promising progression-free survival in advanced non-small cell lung cancer patients with high PD-L1 expression
- Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
- Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
- High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
- CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
- Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
- Narrative review discusses tumor draining lymph nodes as a target for NSCLC therapy
- CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
- Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
- Review of 68Ga-Pentixafor PET/CT Utility in Lung Cancer Diagnosis and Management
- Narrative review examines abscopal effect potential in non-small cell lung cancer multimodality therapies
- Preoperative inflammatory markers linked to survival in resectable NSCLC
- Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
- Narrative review summarizes bispecific antibodies and CAR T-cell therapy for advanced lung cancer
- Meta-analysis shows local consolidative therapy plus systemic therapy improves survival in driver-negative oligometastatic NSCLC
- Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
- Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
- Mini-review of phase III trial data on sublobar resection for small peripheral NSCLC
- Combined radiomics classifier predicts 3-year recurrence in surgically resected stage IA-IIIA non-small cell lung cancer
- HS-20093 shows response in lung cancers in Phase 1a/b trial
- Meta-analysis shows KRASG12C inhibitors improve outcomes versus chemotherapy in KRAS-mutant NSCLC
- Izalontamab brengitecan shows activity in pretreated NSCLC with non-classical actionable genomic alterations
- SABR shows 46% 5-year overall survival in unfit NSCLC patients in phase 2 trial
- Setidegrasib shows antitumor activity in advanced NSCLC and pancreatic cancer with p.G12D variants
- First-line platinum-based chemotherapy associated with disease control and survival in recurrent NSCLC patients
- Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
- First-line osimertinib shows high response rates in EGFR-mutated NSCLC with active brain metastases
- Concurrent TP53 and KRAS alterations show inconsistent survival impact across gastrointestinal cancers
- In Appalachian lung cancer patients, definitive chemoradiotherapy was associated with a 59% incidence of cardiovascular adverse events
- Meta-analysis shows radiomics-based machine learning models predict recurrence risk in non-small cell lung cancer patients
- AI-based PD-L1 scoring shows concordance with expert assessment in 333 NSCLC cases
- PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
- Eight-week mindfulness-based stress reduction reduced fatigue, anxiety, and depression in non-small cell lung cancer patients
- SBRT shows early QoL advantage over CHRT in inoperable stage I NSCLC, but long-term scores converge
- Firmonertinib plus anlotinib shows preliminary efficacy in advanced EGFR-mutant NSCLC
- Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
- BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
- Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
- Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases
- Fulzerasib plus cetuximab shows 69% response in first-line KRAS-mutated NSCLC
- Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
- Global disparities persist in access to molecular diagnostics and novel therapies for advanced NSCLC
- Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
- Perioperative tislelizumab plus chemotherapy improves survival in Chinese patients with resectable NSCLC
- Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
- Phase 2 trial of DS-1062a in pretreated advanced NSCLC with genomic alterations posts no results
- Capmatinib shows efficacy in Chinese NSCLC patients with MET exon 14 skipping mutations
- VATS lobectomy improves overall survival vs open surgery in early-stage NSCLC
- Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
- Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients